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Abstract
Background. Cognitive impairment associated with lifetime major depressive disorder (MDD)
is well-supported by meta-analytic studies, but population-based estimates remain scarce.
Previous UK Biobank studies have only shown limited evidence of cognitive differences related
to probable MDD. Using updated cognitive and clinical assessments in UK Biobank, this study
investigated population-level differences in cognitive functioning associated with lifetimeMDD.
Methods. Associations between lifetime MDD and cognition (performance on six tasks and
general cognitive functioning [g-factor]) were investigated in UK Biobank (N-range 7,457–
14,836, age 45–81 years, 52% female), adjusting for demographics, education, and lifestyle.
Lifetime MDD classifications were based on the Composite International Diagnostic Interview.
Within the lifetime MDD group, we additionally investigated relationships between cognition
and (a) recurrence, (b) current symptoms, (c) severity of psychosocial impairment (while
symptomatic), and (d) concurrent psychotropic medication use.
Results. Lifetime MDD was robustly associated with a lower g-factor (β =0.10, PFDR = 4.7
105), with impairments in attention, processing speed, and executive functioning (β ≥ 0.06).
Clinical characteristics revealed differential profiles of cognitive impairment among case indi-
viduals; those who reported severe psychosocial impairment and use of psychotropicmedication
performed worse on cognitive tests. Severe psychosocial impairment and reasoning showed the
strongest association (β =0.18, PFDR = 7.5 105).
Conclusions. Findings describe small but robust associations between lifetime MDD and lower
cognitive performance within a population-based sample. Overall effects were of modest effect
size, suggesting limited clinical relevance. However, deficits within specific cognitive domains
were more pronounced in relation to clinical characteristics, particularly severe psychosocial
impairment.
Introduction
Major depressive disorder (MDD) is a highly prevalent condition, affecting around one in five
people over their lifetime globally [1–3]. Previous clinical research has shown that individuals
with MDD show cognitive deficits, particularly in executive functioning, working memory,
attention, and processing speed [4–7], as well as affect-related cognitive biases, including negative
information biases for perception, attention, and memory [8,9]. Additionally, there is evidence
that residual cognitive deficits are present in remitted cases [4,10–12]. A recent systematic review
and meta-analysis that investigated studies including individuals remitted from MDD revealed
significant small to moderate deficits in the same domains of cognitive functioning, and showed
worse cognitive functioning associated with recurrent episodes [12].
Meta-analyses are invaluable for investigating patterns of results from smaller studies that are
heterogenous in nature. One disadvantage, however, is that included studies show differential
procedures of participant inclusion and recruitment, of which some will be more focused on
certain clinical populations (e.g., allowing bipolarity or including participants after antidepres-
sant treatment). As a result, meta-analytically derived effect sizes may overestimate cognitive
impairment related toMDD compared with the general population. Understanding the degree of
impairment associated with lifetime MDD (current or past diagnosis) in the general population
thus requires further investigation within a sufficiently powered community-based sample. This
summarizes the added value of population-based studies which are not biased by specific clinical
characteristics and that are sufficiently powered to detect potentially modest effect sizes.
UK Biobank is a large-scale adult population-based study that is well-suited to investigate
population-level cognitive differences related to lifetime MDD. Previous population-based
studies that investigated baseline assessments of theUKBiobank cohort study indicatedmodestly
decreased visuospatial memory performance in participants with lifetimeMDD [13], but showed
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comparable cognitive performance to controls for other cognitive
measures of reasoning, reaction time, and memory [13,14]. Robust
evidence from population-based studies is currently limited, so that
the degree and patterns of cognitive impairment in community-
based individuals with lifetime MDD remain uncertain.
Of note, UK Biobank follow-up assessments were recently
extended to include updated cognitive measures with improved
reliability [15,16]. These tests also cover a broader range of cogni-
tive domains previously implicated in MDD and show sufficient
performance variability within the healthy population. Further-
more, previous mood disorder groupings relied on a combination
of self-report and relatively unstructured questionnaire items,
whereas the more recent lifetimeMDD assessments in UK Biobank
were based on a Structured Diagnostic Interview Questionnaire,
that is the Composite International Diagnostic Interview (CIDI-SF)
[17]. In the current study, we used the opportunity provided by
these updated assessments to further investigate patterns of cogni-
tion functioning in lifetime MDD within the large population-
based UK Biobank sample.
Furthermore, the novelty and clinical relevance of this study was
increased by additionally conducting a population-based investiga-
tion of clinical characteristics associated with cognitive functioning.
The first clinical variable of interest was recurrence of depressive
episodes, given the usually highly recurrent nature of MDD and the
ongoing discussions with regard to “scar theories” (which propose
that disease-related psychological or biological changesmay result in
a predisposition to future depressive episodes) [18]. Although earlier
research has not consistently reported recurrence of MDD being
associated with lower cognitive functioning [10,19], recent evidence
suggests that cognitive deficits do accumulate with repeated episodes
[12]. Furthermore, although no optimal measure ofMDD remission
was available from UK Biobank assessments, we investigated asso-
ciations with the putative presence of current depressive symptoms.
There is a general consensus that low mood can negatively affect
cognitive performance, andmore pronounced cognitive impairment
for symptomatic individuals is supported by previous meta-analytic
studies [6,10,20]. However, another meta-analysis showed similar
effect sizes for the current and remitted state [4], and associations
with depressive symptoms may be attenuated within the general
population [21]. Third, we addressed associations between psycho-
social functioning during the depressive episode and subsequent
cognitive deficits. Previous research suggests that cognitive deficits
contribute to impaired psychosocial functioning [22–24], which
impacts on quality of life. Furthermore, cognitive deficits were found
to mediate of decreased work performance, contributing to the
overall cost attributable toMDD [25,26]. The fourth clinical variable
of interest was use of psychotropic medication concurrent with
cognitive assessment. Pharmacological treatment is expected to have
a complex influence on cognitive functioning, although reliable
evidence is limited [27]. Meta-analyses suggest that some antide-
pressants may improve cognition [28,29], but these results appear to
be specific to particular treatments [30–32], while for other treat-
ments, medication side-effects may potentially affect cognitive per-
formance negatively [6,14,33]. Given the variety of psychotropic
medications, we did not aim to investigate their differential effects,
but rather investigated the overall association between psychotropic
medication and cognitive functioningwithin the general population.
In summary, the aim of the current study was to investigate
cognitive functioning in the context of lifetime MDD within
the general population, as conducted within the large-scaled
population-based UK Biobank sample. Robustness of associations
was tested via inclusion of different combinations of demographic,
education, and lifestyle (smoking, alcohol consumption, and body
mass index [BMI]) [34,35] covariates. We also examined clinical
characteristics that are considered relevant to cognitive functioning
in the context of lifetime MDD and may therefore influence the
association: (a) recurrence of depressive episodes, (b) current MDD
symptomatology, (c) severe psychosocial impairment (while symp-
tomatic), and (d) use of psychotropic medication (at time of assess-
ment). These characteristics were hypothesized to distinguish case
subgroups withmore severe cognitive impairment, or specifically for
psychotropic medication, either increased or reduced impairment.
Methods
Participants
Adults (40–69years) were recruited for participation in UKBiobank
(http://www.ukbiobank.ac.uk) between 2006 and 2010 [36]. The
present study included participants with data for at least one of the
six neuropsychological test scores currently investigated from the
third UK Biobank assessment (2014 onwards; N=28,480). Partici-
pants with self-reported neurological conditions were excluded from
all analyses. A g-factor, representing general cognitive function, was
derived from all remaining participants with complete data for
included cognitive test measures (N =13,589). When assessing
individual tasks, complete cognitive data was not required. Partici-
pants with specific psychiatric disorders or an unclassified/missing
lifetime MDD status were excluded from further analyses
(SupplementaryMaterials 1, Figure S1). Following exclusion criteria,
N =14,877 individuals (ncases = 4,486, Mage = 63.5, SDage = 7.4, age
range 45–81years, 52% female) were included across all analyses,
with sample sizes ranging from N=7,457 to N =14,386 per case–
control analysis.
Measures and procedure
At the third assessment, participants visited the assessment center
where they provided demographic and health information in
response to a series of touchscreen questions and completed com-
puterized cognitive tests on the touchscreen. Medical history and
currentmedication use were assessed during interviews led by health
professionals. Furthermore, participants completed a web-based
Mental Health Questionnaire (MHQ) at home [37], which informed
lifetimeMDD classifications. Most participants (all those with com-
plete cognitive data) completed the MHQ between 2.2 years before
and 0.4 years after their assessment center visit. UKBiobank received
Research Ethics Committee (REC) approval for the center assess-
ments (ref 11/NW/0382), also later amended to cover the MHQ,
and all participants provided informed consent before assessment
(http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=200).
Classification of lifetime MDD
Case–control classification was based on the short form of the
Composite International Diagnostic Interview (CIDI-SF) [17],
administered as part of the MHQ [37]. This included two binary
screening questions regarding ever having experienced (a) depres-
sive feelings or (b) loss of interest, for a period of two ormoreweeks.
Participants who responded “Yes” to either question then answered
a question about the lifetime number of depressive episodes, fol-
lowed by six binary questions on experience of other DSM-IV
MDD symptoms during their worst episode, including:
(c) feelings of worthlessness, (d) tiredness, (e) difficulty concen-
trating, (f) suicidal thoughts, (g) changes in sleeping pattern, and
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(h) changes in weight. Summed responses to all eight depression
symptom questions provided a symptom score (range 0–8). Par-
ticipants were also asked how often they had experienced depres-
sive feelings/loss of interest during their worst episode, how long
these feelings lasted, and whether they interfered with their “roles,
life or activities” (psychosocial impairment). Participants were
classified as lifetime MDD cases if all of the following applied [37]:
1. Summed symptom score≥ 5.
2. At worst, symptoms experienced “almost every day” or “every
day,” and lasted “most of the day” or “all day.”
3. Symptoms impaired psychosocial functioning “somewhat” or
“a lot.”
Clinical characteristics
Within individuals who were classified with lifetime MDD as
described above, we further identified four clinical characteristics:
(a) recurrent MDD, reflecting more than one depressive episode,
(b) putative current MDD symptoms concurrent with the cognitive
assessment, derived from responses on the touchscreen question-
naire (Supplementary Materials 2), (c) severe psychosocial impair-
ment (at the time of the depressive episode), indicated by the
maximum CIDI-SF symptom score of eight in combination with
the maximum score for psychosocial impairment [37]; and
(d) concurrent use of psychotropic medication, which was derived
from reported use of antidepressant (94.6%), antipsychotic (3.9%),
or anxiolytic (1.5%) medication as assessed during the nurse-led
interview (Supplementary Materials 3, Figure S2).
Cognitive assessment
In the current study, we considered cognitive tests from the third
UK Biobank assessment. We included data from the following
cognitive tests:
1. Digit symbol substitution test (DSST)
2. Trail making test, alphanumeric trail (TMT-B)
3. Numeric memory (NM)
4. Matrix pattern completion (Matrix)
5. Verbal numeric reasoning (VNR)
6. Tower rearranging (Tower)
This selection comprises all updated cognitive test data available at
time of analysis (DSST, TMT-B,Matrix, andTower), and additionally
included two cognitive tests repeated at this assessment that were also
administered at earlier UK Biobank assessments (VNR and NM).
Further details on each cognitive test can be found in Table 1.
Psychometric properties, advantages, and limitations of the UK
Biobank cognitive tests have been discussed in detail elsewhere [16].
Education, lifestyle, and parental illness history
Measures of education, alcohol consumption, and smoking were
derived from touchscreen questionnaire responses (Supplementary
Materials 4). For education, a multiple-choice question allowed
participants to report all qualifications. Participants were classified
into one of five categories depending on the highest qualification
they had attained. Alcohol consumption was measured as alcohol
units per week [38]. Past smokers were categorized by pack years
[39] quartiles, with participants who had never regularly smoked in a
fifth category. BMI (in kg/m2) was derived by the UK Biobank team
from physical measurements. Participants also reported for a num-
ber of listed illnesses whether their biological mother or father ever
experienced the illness. Parental history of severe depression (from
either parent) was derived from all available assessment responses.
Statistical analysis
Statistical analyses were performed in R (version 3.2.3). Continuous
variables were visually inspected and log-transformed where nec-
essary to more closely approximate normal distribution. We
reversed the TMT-B variable before statistical modeling, so that
for all tests, higher scores represented better performance. For all
Table 1. Descriptions of cognitive tests
Test Description Cognitive domains Variable Range
DSST Presented with a key grid containing digit-symbol pairs, the
participant had one minute to indicate which number
corresponded to each of the symbols in the task grid.
Processing speed and attention Total correct score 0–89
TMT-B Digits and letters were scattered around the screen in circles.
The participant was asked to click on them sequentially,
alternating between digits and letters (1-A-2-B-3-C, etc.)
Executive functions (mental
flexibility, complex attention)
and processing speed
Time to completion (s)
reversed in analyses
20–300
NM Every trial, a sequence of digits was briefly presented on
screen, after which the participant was asked to recollect it
from memory. If answered correctly, the sequence length
increased with one digit.
Working memory and attention Maximum digits remembered
correctly
2–12
Matrix Presented with a series of matrix pattern blocks that each
missed one element, the participant was asked to select the
element that best completed the pattern from a range of
choices.
Reasoning ability (abstract) Total correct score 0–15
VNR The participant had 2min to complete as many multiple-
choice reasoning questions as possible.
Reasoning ability (verbal, numeric)
and processing speed
Total correct score 0–13
Tower Presented with a series of illustrations displaying three
differently colored hoops on three pegs, the participant
was asked howmanymoves it would take to re-arrange the
hoops into another specific position.
Executive functions (strategy,
planning) and working memory
Total correct score 0–18
Abbreviations: DSST, digit symbol substitution task; Matrix, matrix pattern completion; NM, numeric memory; TMT-B, trail making test B (alphanumeric trail); Tower, tower rearranging; VNR,
verbal numeric reasoning.
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outcome variables, negative regression coefficients thus indicated
negative associations with cognitive performance. Regression
coefficients are standardized throughout. Significance level was
determined by a two-tail threshold of α=0.05.
Derivation of g-factor
We derived a g-factor as single measure of general cognitive
functioning [40] by application of Principal Component Analysis
(R function “prcomp”) including only complete observations (n=
13,589), extracting scores on the first principal component. This
derived g-factor accounted for 45.0% of the test score variance.
Component loadings of themodel were all in the expected direction
(loadings range 0.34–0.47; Supplementary Materials 5, Table S1,
and Figure S3).
Statistical modeling
Associations between lifetime MDD and cognitive performance
were tested using linear models. Each model included lifetime
MDD as the predictor of interest and a cognitive score as the
outcome variable. Primary models included age and sex as con-
founds (Tables 2 and 3). Additional models also included
(a) education, (b) lifestyle factors (alcohol, smoking, and BMI),
and (c) both education and lifestyle factors (full model) as potential
confounds. These results were false discovery rate (FDR) corrected
across the 24 test-specific models and separately across the four g-
factor models. Additional explorative analyses assessed age by
MDD interactions or effects of parental history of severe depression
on cognitive functioning.
With the aim of investigating whether cognitive performance
related to specific clinical features of depression, we also examined
relationships, within the case group only, with recurrent depres-
sion, putative current depressive symptoms, impact on psychoso-
cial functioning, and psychotropicmedication use. First, we tested a
linear model including participants classified with lifetime MDD
only (n=2,179; Figure 2A) that predicted g-factor from all four
clinical characteristics, including age and sex as covariates. Given
the large degree of overlap between clinical characteristics within
our sample, these variables were entered as simultaneous predictors
Table 2. Demographic variables for participants who completed all cognitive tasks
Control n = 5,221 Case n = 2,236 Effect size
Age (years), mean (SD)a 64.7 (7.3) 62.5 (7.1) 0.30A***
Sex female, n (%)b 2,379 (45.6) 1,503 (67.2) 0.20B***
Educationb n.s.
Incomplete, n (%) 263 (5.0) 87 (3.9)
Compulsory, n (%) 600 (11.5) 267 (11.9)
Continued, n (%) 304 (5.8) 121 (5.4)
College, n (%) 1,327 (25.4) 561 (25.1)
University, n (%) 2,710 (51.9) 1,188 (53.1)
Missing data, n (%) 17 (0.3) 12 (0.5)
Alcohol unitsc 0.007C***
Median (IQR) 10.7 (15.6) 9.0 (14.9)
Missing data, n (%) 317 (6.1) 162 (7.2)
Smoking
Lifetime regular smoker, n (%)b 1,079 (20.7) 624 (27.9) 0.08B***
Pack years, median (IQR)c 14.8 (17.5) 16.5 (22.4) 0.005C**
Missing data, n (%) 86 (1.6) 34 (1.5)
BMIc 0.006C***
Median (IQR) 25.5 (5.0) 26.2 (6.0)
Missing data, n (%) 204 (4.6) 112 (5.0)
Patental history severe depressionb 0.14B***
Yes, n (%) 364 (7.0) 357 (16.0)
No, n (%) 4,494 (86.1) 1,715 (76.7)
Missing data, n (%) 363 (7.0) 164 (7.3)
Abbreviations: BMI, body mass index; IQR, interquartile range; n.s., nonsignificant; SD, standard deviation.
aIndependent t-test.
bChi-squared test.
cKruskal–Wallis test.
AHedge’s g.
BCramer’s V.
Cη2.
**p < 0.01.
***p < 0.001.
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in order to model their unique contributions to cognitive function-
ing. Second, we further explored whether the four clinical charac-
teristics were associated with differential profiles of cognitive
performance. Using the same approach, we tested another six
univariate linear models (applying FDR-correction over six tests)
that predicted each cognitive test scores from all four clinical
characteristics, including age and sex as covariates.
Results
Sample characteristics
Table 2 summarizes demographic and lifestyle information on
participants who completed all cognitive tests. The MDD group
included a higher proportion of females (45.6% of controls, 67.2%
of cases, χ2(1) = 293.2, p < 2.2 1016) and individuals with paren-
tal history of severe depression (7.0% of controls, 16.0% of cases,
χ2(1) = 146.7, p < 2.2 1016). MDD cases were also younger (M
difference = 2.2 years, t(4357.9) = 12.1, p < 2.2 1016), had higher
BMI (Mdn difference = 0.7 kg/m2, H(1) = 40.1, p = 2.4 1010),
were more often lifetime regular smokers (20.7% of controls,
27.9% of cases, χ2(1) = 46.0, p = 1.2 1011), and among smokers,
they had smoked more cigarettes (Mdn difference = 1.8 pack
years, H(1) = 7.8, p = 5.3 103). Conversely, control group
participants reported more alcohol consumption (Mdn differ-
ence = 1.7 units/week, H(1) = 46.6, p = 8.7 1012). Education
did not significantly differ between groups (χ2(4) = 5.6, p = 0.23).
Case and control sample sizes for individual cognitive tests, as
well as test descriptive statistics, can be found in Table S2
(Supplementary Materials 6).
Associations between lifetime MDD and cognitive performance
Results indicated significant associations between lifetime MDD
and cognitive performance (Table 3). The primary models consis-
tently showed lower cognitive performance for the case group
relative to controls with small effect sizes in terms of the g-factor
(β=0.10, PFDR= 4.7 105) and four of the six cognitive tests
(DSST, β=0.13, PFDR = 1.1 107; TMT-B, β=0.08, PFDR =
1.1 103; VNR, β=0.06, PFDR = 2.0 103; Tower, β=0.06,
PFDR = 3.4 102) (Figure 1). These results were robust over
subsequent models that additionally included confounding vari-
ables, and all significant results (except for the Tower lifestyle
model) survived multiple testing correction. Associations between
cognitive performance and covariates are reported in Table S3
(Supplementary Materials 7). Explorative analyses did not suggest
Table 3. Linear model coefficients for the association between lifetime mood disorder and cognitive performance
Model 1 Model 2 Model 3 Model 4
Primary model (+Education) (+Lifestyle) Full model
g-factor
β-coefficient 0.10*** 0.10*** 0.08*** 0.10***
(95% CI) (0.15, 0.05) (0.15, 0.06) (0.14, 0.03) (0.15, 0.05)
DSST
β-coefficient 0.13*** 0.13*** 0.12*** 0.13***
(95% CI) (0.18, 0.09) (0.18, 0.09) (0.17, 0.08) (0.18, 0.08)
TMT-B
β-coefficient 0.08*** 0.08*** 0.08** 0.09***
(95% CI) (0.13, 0.04) (0.13, 0.04) (0.13, 0.03) (0.14, 0.04)
NM
β-coefficient 0.03 0.03 0.02 0.03
(95% CI) (0.08, 0.02) (0.08, 0.01) (0.07, 0.03) (0.08, 0.02)
Matrix
β-coefficient 0.03 0.03 0.00 0.01
(95% CI) (0.07, 0.02) (0.08, 0.02) (0.05, 0.06) (0.06, 0.04)
VNR
β-coefficient 0.06*** 0.06*** 0.05* 0.07***
(95% CI) (0.10, 0.03) (0.10, 0.03) (0.09, 0.01) (0.10, 0.03)
Tower
β-coefficient 0.06* 0.06* 0.05* 0.06*
(95% CI) (0.11, 0.01) (0.11, 0.01) (0.11, 0.00) (0.11, 0.01)
Bold values represent PFDR < 0.05.
Abbreviations: CI, confidence interval; DSST, digit symbol substitution task; g-factor, derivedmeasure of general cognitive performance; Matrix, matrix pattern completion; NM, numericmemory;
TMT-B, trail making test (alphanumeric trail); Tower, tower rearranging; VNR, verbal numeric reasoning.
*p < 0.05.
**p < 0.01.
***p < 0.001.
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any age by MDD interaction effects (Supplementary Materials
8, Table S4) or effects of parental history of severe depression
(Supplementary Materials 9, Table S5) on cognitive functioning.
Associations between clinical characteristics and cognitive
performance
For the associations between clinical characteristics and cognitive
impairment, as measured by g-factor, we found no effect of recur-
rent depression (β = 0.02, p =0.56), and a very modest, nonsignif-
icant point estimate for putative current symptoms at time of
assessment (β =0.07, p=0.15). Conversely, retrospectively
reported severe psychosocial impairment during the depressive
episode was significantly associated with lower g-factor (β =0.14,
p =1.5 102). Use of psychotropic medication showed a small,
nonsignificant point estimate for its association with general cog-
nitive functioning (β =0.10, p=0.10).
Further exploration within the lifetimeMDD case group revealed
differential cognitive profiles related to clinical characteristics
(Figure 2B–E and Supplementary Materials 10, Table S6). Severe
psychosocial impairment was associated with worse VNR perfor-
mance (β =0.18, p= 1.2 105, PFDR = 7.5 105). Further-
more, results indicated nominally significant associations with
lower TMT-B performance for severe psychosocial impairment
(β =0.11, p= 2.3 102, PFDR = 0.07) and psychotropic medica-
tion (β =0.13, p= 2.7 102, PFDR = 0.16).
Discussion
The findings of the current study describe a robust association
between lifetime MDD and lower general cognitive performance
within a population-based sample. The DSST, TMT-B, VNR, and
Tower results further indicate that executive functioning, proces-
sing speed, and aspects of reasoning were predominantly affected.
These effects were of modest overall effect size (β =0.10 for
general cognitive performance), suggesting that they are of limited
clinical relevance, although such differences may have substantial
Figure 1. Visualization of the primarymodel results for (A) g-factor, (B) DSST, (C) TMT-B, (D) NM, (E) Matrix, (F) VNR, and (G) Tower. Graphs display case-control group differences in
cognitive performance after adjustment for confounders (i.e., age and sex were regressed out). Specifically, they show significant but modest associations of lifetime MDD
classification with lower general cognitive performance (g-factor), and with lower performance on DSST, TMT-B, VNR, and Tower. *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations:
DSST, digit symbol substitution task; g-factor, derivedmeasure of general cognitive performance; Matrix, matrix pattern completion; NM, numericmemory; TMT-B, trail making test
(alphanumeric trail); Tower, tower rearranging; VNR, verbal numeric reasoning.
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Figure 2. (A) Venn diagram of all participants classified with lifetime MDD and each of the four the clinical characteristics recurrent depression, putative current symptoms, severe
psychosocial impairment, and psychotropic medication. These clinical characteristics were investigated within the group of case participants. (B–E) Cognitive profiles associated
with the clinical characteristics (B) recurrent depression, (C) putative current symptoms, (D) severe psychosocial impairment (while symptomatic), and (E) use of psychotropic
medication (at time of assessment). Points represent points estimates of the β-coefficient within the case models, whereas lines reflect the 95% confidence interval of the
β-coefficient. *p < 0.05, ***p < 0.001. Abbreviations: DSST, digit symbol substitution task; Matrix, matrix pattern completion; NM, numeric memory; TMT-B, trail making test
(alphanumeric trail); Tower, tower rearranging; VNR, verbal numeric reasoning.
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consequences for whole populations. Comparisons within the case
group, however, showed that psychosocial functioning (while
symptomatic) and use of psychotropic medication (at time of
assessment) predicted the lowest measures of cognitive perfor-
mance. These clinical characteristics also showed differential pro-
files of cognitive impairment, whereby severe psychosocial
impairment was associated with reasoning (VNR) deficits. Severe
psychosocial impairment, along with use of psychotropic medica-
tion, was also related to moderately lower mental flexibility and
processing speed (TMT-B). These results highlight (i) that cognitive
functioning is impaired among individuals with current, but also
past MDD, and (ii) that deficits within specific cognitive domains
may be more pronounced—and therefore of potential clinical rele-
vance—in relation to retrospectively reported psychosocial impair-
ment (during the depressive episode) and concurrent use of
psychotropic medication.
Meta-analyses of small case–control studies have previously
indicated cognitive deficits associated with current and remitted
MDD within the domains of processing speed, executive function-
ing, memory, and attention [4,12]. This study corroborates such
previous findings, but we also note that these population-level effect
sizes are smaller than in traditional case–control studies. Of note,
psychosocial impairment while symptomatic was also significantly
associated with greater cognitive deficits in individuals with lifetime
MDD, and we found some evidence for an association between
psychotropic medication use and lower processing speed. This
implicates that clinical studies that recruit from treatment centers,
and thereby include participants from a patient group more likely
to experience severe psychosocial impairment and/or use psycho-
tropic medication, may show inflated effect sizes in comparison
with the general population because of their sample characteristics.
Psychosocial impairment during the depressive episode was
found to be associated with lower cognitive functioning at subse-
quent assessment. Because other clinical characteristics such as the
putative presence of current depressive symptoms were taken into
account, this suggests that the impact of a depressive episode on
quality of life may not be limited to the symptomatic phase. This
result is consistent with previous adult clinical studies [23] andmay
reflect a subgroup of remitted individuals vulnerable to cognitive
impairment, who potentially also experienced greater cognitive
deficits during the depressive episode. Previous clinical research
also showed that cognitive impairment in remitted MDD was
associated with psychosocial dysfunction in multiple domains
[24]. Future research will need to address the underlying causality
of the relationship between severe psychosocial impairment and
impaired cognitive functioning in the context of lifetime MDD. If
functional impairment persists specifically in remitted individuals
who experience residual cognitive deficits, quality of life could
be increased with interventions that target cognitive symptoms
[24,41–43].
Findings of the current study did not indicate robust associations
of cognitive impairment with recurrent depressive episodes or puta-
tive current MDD symptoms, and less robust associations with
psychotropic medication. Thus, within the healthy and nonclinical
UKBiobank population, theseMDDcharacteristics were less relevant
to the association between lifetime MDD and cognitive impairment.
Of note, however, the current investigation was limited by the
phenotypes available in UK Biobank. Classification of lifetime
MDD was based on the CIDI-SF, which, although based on
diagnostic criteria and well validated, is still limited by reliance
on retrospective self-report. As a consequence of the interval
between cognitive and clinical assessment, no certain measure of
remission or continuous measure of depressive symptoms at time
of cognitive assessment could be established. Constrained by these
limitations, the characteristic of putative current symptoms was
locally derived from responses to the touchscreen questionnaire to
explore the effect of depressive symptoms, but one should note
that this variable was not previously validated. Therefore, it
remains unclear whether differences in cognitive functioning
within the UK Biobank sample depend on the state of current
depression, or rather reflect a trait that also persists after remis-
sion. Given the aim of the current study to investigate (residual)
cognitive impairment associated with lifetimeMDD in the general
adult population, the mid-late life age range of UK Biobank
participants at the time of the third assessment could also be
considered a limitation. However, the cohort has been previously
described as a relatively healthy mid-late life cohort [37], from
which we excluded individuals with reported neurological or
degenerative conditions from the current study.
The current study benefited from the availability of newer, more
reliable cognitive assessments in UK Biobank, but as such also
imposed the limitation of a cross-sectional design. Although
explorative analyses did not suggest any age-interaction effects
indicative of accelerated cognitive ageing, nor any parental history
effects suggesting cognitive vulnerability, it remains unclear when
the MDD-related cognitive differences emerged. Future large-scale
longitudinal research will be needed to unravel the relationship
betweenMDD and cognitive impairment over the disease course as
well as the lifespan.
In summary, the present findings suggest that lifetime MDD
relates to impaired cognitive functioning among adults in their
mid-late life, with most prominent deficits in the cognitive domain
of processing speed (DSST). Severe psychosocial impairment during
the depressive episode was associated with greater overall cognitive
impairment, and specifically on tasks of reasoning (VNR) and
mental flexibility and processing speed (TMT-B). Furthermore,
clinical characteristics showed differential profiles of impairment
that were of modest effect. These findings add to meta-analytic
evidence by providing accurate population-level estimates, which
is an important foundation for future studies addressing cognitive
functioning in the context of MDD. Longitudinal trajectories of
cognitive performance in lifetime MDD and the differential influ-
ences of pharmacological treatments on these trajectories are impor-
tant targets for further research. The longitudinal association
between psychosocial impairment while symptomatic and subse-
quent cognitive impairment, also when remitted, reflects their likely
impact on quality of life and suggests that both cognitive and
psychosocial functioning should be key targets in the treatment
of MDD.
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